Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.60 |
| ▸ | GSK3B | P49841 | 6/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13119430 | 0.92 | CDK2 (0.72) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL13119302 | 0.87 | CDK2 (0.67) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL13119536 | 0.85 | CDK2 (0.70) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL14581650 | 0.84 | GSK3B (0.59) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL14581651 | 0.83 | GSK3B (0.55) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL14301598 | 0.82 | GSK3B (0.66) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL13119676 | 0.81 | CDK2 (0.65) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL14301724 | 0.81 | GSK3B (0.57) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL14043167 | 0.81 | CDK2 (0.58) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL13120274 | 0.80 | CDK2 (0.62) | CDK2GSK3BCCNA2CCNA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | CDK2 1/4885GSK3B 749/4885CCNE1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.